tbuckley/cabot-search huggingface dataset:
Outcome of CML patients with ABL tyrosine kinase mutations after hematological resistance to imatinib
Authors: A. Hochhaus, S. Kreil, P. La Rosée, M. C. Mueller, U. Schwindel, M. Emig, B. Hanfstein, T. Lahaye, U. Berger, R. Hehlmann
Journal: Journal of Clinical Oncology (2004)

6540 Background: Although responses in chronic phase (CP) CML to imatinib have been quite durable, a significant proportion of pts with advanced disease develop resistance after short period of therapy. The mechanisms of resistance are diverse, but in most cases mutations are found that change amino acids within the kinase domain of BCR-ABL. Methods: We analyzed the outcome of 53/117 pts with BCR-ABL mutations (45%) detected by direct sequencing at the time of resistance. Median exposure to imatinib was 12 months (range 1–30). Prior to imatinib therapy, 21 pts were in CP, 18 in accelerated phase (AP), 13 in myeloid and one in lymphoid blast crisis (BC). Mutation specific restriction digests of RT-PCR products (n=129) were employed to track the proportion of mutated clones. Results: Resistance was associated with 22 different mutations affecting 18 amino acids of the P-loop area (n=21), T315I (n=8), the activation loop (n=9), and other sites (n=18). In 3 pts, 2 different mutations were found. Median time to resistance was 0.7 yrs in CP, 1.3 yrs in AP and 1.2 yrs in BC. After relapse, imatinib was continued for 0–30 (median 4) months. Dose was escalated in 18 pts. In 27 pts, imatinib was combined with other drugs, in 22 pts with ara-C. After imatinib withdrawal, treatment was continued with hydroxyurea, n=27; ara-C, n=21; other drugs, n=38, allogeneic stem cell transplantation, n=7. In 4 cases, imatinib was reintroduced leading to a hematologic remission in one patient. Overall survival after resistance was 1.2 yrs (0–3.1). A reduction of mutated BCR-ABL to a level of <2% was seen in 4 pts after imatinib withdrawal. Median survival after resistance was 0.8 yrs for P-loop mutations, 1.5 yrs for others (n.s.). Conclusions: (i) The outcome of CML pts resistant to imatinib is heterogeneous with the most aggressive course in pts with P-loop mutations. (ii) The time course of the onset of mutations suggests both preexistence and new occurence in individual cases. (iii) Approaches to handle resistance include dose escalation and combination therapy leading to a temporary stabilization of the disease. (iv) Withdrawal of imatinib is suggested to stop the clonal selection of resistant cells. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis Pharma, Nürnberg, Germany
TCT-654 Balloon vs Computed Tomography Sizing of the Aortic Annulus for Transcatheter Aortic Valve Replacement
Authors: Jose F. Condado, James Stewart, Hanna A. Jensen, Stamatios Lerakis, Sung Min Ko, Arthur Stillman, Mohammad H. Rajaei, Kreton Mavromatis, Chandan Devireddy, Eric Sarin, Bradley G. Leshnower, Robert Guyton, Brian Kaebnick, Amjad Syed, Vinod Thourani, Peter C. Block, Vasilis Babaliaros
Journal: Journal of the American College of Cardiology (2015)
Endoscopic hemostasis for tumor bleeding using intraductal radiofrequency ablation
Authors: Takeshi Ogura, Wataru Takagi, Saori Ueno, Toshihisa Takeuchi, Shinya Fukunishi, Kazuhide Higuchi
Journal: Endoscopy (2016)

Bleeding hepatobiliary tumors can sometimes be critical in patients with advanced malignancy. Several methods can be used to achieve hemostasis, such as the placement of a covered metal stent or vessel coiling under angiographic control. If tumor bleeding occurs near the mid or lower bile duct, a fully covered metal stent can be placed for hemostasis; however, this method may be challenging if there is bleeding at the hepatic hilum or when bleeding is inactive. Recently, intraductal radiofrequency ablation (RFA) has been reported to provide prolonged stent patency [1] [2]. This technique may however also be clinically useful for achieving hemostasis. Herein, we present technical tips for achieving hemostasis of tumor bleeding using intraductal RFA.
The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older
Authors: Satish F. K. Lubeek, Lieke J. van Vugt, Katja K. H. Aben, Peter C. M. van de Kerkhof, Marie-Jeanne P. Gerritsen
Journal: JAMA Dermatology (2016)

The number of very elderly (≥80 years) is rapidly growing worldwide. Basal cell carcinoma (BCC) are common in this age group and treatment is often challenging in this population.Obtaining an overview of the epidemiology and clinicopathological features of BCC in the very elderly to guide clinicians and policy makers.A systematic review of literature was performed using PubMed, Excerpta Medica Database (EMBASE), and the Cochrane Library. Study selection, quality assessment, and data extraction was performed by 2 independent reviewers. For quality assessment (including the risk of bias) the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist was used, combined with the Quality Rating Scheme for Studies and Other Evidence. Data were described though a narrative synthesis and tabulation.Of 13 628 studies identified, 83 studies were included and quality assesment was performed for 76 studies; 27 studies (representing >350 000 patients) were found that included age-specific incidence rates of BCC in the very elderly. High and increasing incidence rates of BCC in the very elderly were found ranging from 13 to 12 112 per 100 000 person-years, strongly depending on factors like study population and clinical setting. Basal cell carcinoma in the very elderly were more common in men, mostly of the nodular subtype, and located in the head and neck region. Interpretation and generalization of the data was limited by the heterogeneity of study populations, methods, and outcomes. Data concerning impact on health-related quality of life (HRQoL) and prognostication were scarce.The incidence of BCC among the very elderly is high and increasing. Epidemiologic and clinicopathological data from current literature provide only limited guidance in clinical decision making owing to heterogeneity and scarcity. Future research should focus more specifically on BCC in the very elderly, together with prognostication and their relation with HRQoL in both the short and longer term.
Rituximab-related (R-R) reactivation of hepatitis B virus (HBV) in lymphoma: Analysis of FDA safety reports and a systematic literature review with meta-analysis.
Authors: A. M. Evens, B. Chiu, Y. Su, M. Dai, B. Jovanovic, B. Fintel, D. Ganger, T. Chen, S. Lin, C. Kuo
Journal: Journal of Clinical Oncology (2010)

8096 Background: In 2004, based on 3 case reports, the FDA warned health care professionals of R-R HBV-reactivation (HBV-R). Since then, additional cases have been reported. However, the scope and characteristics of this association remain largely unknown. Methods: From 1997-2009, we identified 183 unique cases of R-R HBV-R: 169 from medical literature, 4 through institutional surveillance, while only 10 cases were reported to the FDA MedWatch system. Case reports were examined for quality/completeness and case series for incidence and mortality. Results: Of 169 R-R HBV-R cases reported in the literature, 26 were published as case reports and 143 as case series. Of the 26 case reports and 4 surveillance cases (n=30), 18 patients (pts) had + HBV core antibody (HBcAb+) and 12 HBV surface antigen (HBsAg+). The median number of rituximab doses prior to HBV-R was 6 (3-10). Median time from last rituximab dose to HBV-R was 4 months (0-21; 30% occurred >6 months). 60% of pts experienced fulminant liver failure, while the HBV-R mortality rate was 40%. Quality comparison and completeness of source data from the literature and surveillance reports were significantly superior to FDA reports (overall completeness ratio: 2.18, p=0.015). In terms of R-R HBV-R case series reports (n=143), 80 pts had HBcAb+ and 63 HBsAg+ (Table); 5 series included a control group. R-R therapy was associated with a significant increase in HBV-R (risk ratio 13.6, 95% CI 3.9, 72.2; p<0.0001), although the incidence and mortality varied greatly across studies. Conclusions: A paucity of R-R HBV-R safety reports have been reported to the FDA, of which are poor quality. Meta-analysis of the medical literature showed a significant increase in HBV-R with R-R therapy. However, incidence and mortality rates varied significantly across studies. Prospective examination of R-R HBV-R is warranted. Case series* Incidence of R-R HBV-R (vs. non R-R) Mortality rate# HBcAb+^ 8% (0.1%) 43% 45%, all R-R 40% 2.7% (0.8%) 0 24% (0) 20% 27%, all R-R NR 6% (0) 0 HBsAg + 16% (0) NR 65%, all R-R NR 80%, all R-R 17% Abbreviation: NR, not reported. * 89% cases from retrospective series. # From R-R HBV-R. ^ None with HBV prophylaxis. No significant financial relationships to disclose.
Hypoxia Regulates Eph/Ephrin-Facilitated Adhesion and Proliferation Of Chronic Myeloid Leukemia Cells
Authors: Xuan Zhou, Liu Xiaoli, Na Xu, Yajuan Xiao, Zhengshan Yi, Guanlun Gao, Jinfang Zhang, Bintao Huang, Qingfeng Du
Journal: Blood (2013)
Definitive Erythro-Myeloid Progenitors (EMPs) Emerge in the Myb-/- Embryo and Retain the Capacity to Differentiate into Macrophages
Authors: Jenna M. Frame, Katherine H. Fegan, Seana C. Catherman, Joanna Tober, Anne D. Koniski, Kathleen E McGrath, James Palis
Journal: Blood (2015)
Determination of the ideal number of lymph nodes to examine to optimize survival in patients with esophageal carcinoma: Data from the surveillance epidemiology and end results database
Authors: S. S. Groth, B. A. Whitson, Z. Li, T. E. DeFor, R. A. Kratzke, M. A. Maddaus
Journal: Journal of Clinical Oncology (2008)

4528 Background: Accurate nodal staging has important prognostic and therapeutic implications for esophageal cancer patients yet there is a lack of information in the literature to guide clinicians regarding the minimum number of lymph nodes (LNs) that should be examined. The aim of this study was to determine the ideal number of LNs that need to be examined pathologically to optimize overall and cancer-free survival in esophageal cancer patients. Methods: Using the Surveillance Epidemiology and End Results (SEER) database, we identified patients who were diagnosed with invasive esophageal carcinoma from 1988 through 2003 and who had a known number of LNs examined pathologically. Because of the potential for confounding, we excluded patients with either metastatic disease or with a hospice, autopsy or death certificate as their only reporting source. After stratifying patients (0, 1 to 5, 6 to 10, 11 to 15, 15 to 20 and 21 or more LNs examined) we assessed the (crude) association between the number of lymph nodes examined and survival using the Kaplan-Meier method. To adjust for potential confounding covariates, we used a Cox proportional hazards regression model. Results: Of the 29,659 patients in the SEER database with esophageal cancer, 8,940 met our inclusion criteria. We noted a significant difference (p<0.0001) between the LN groups with regards to unadjusted overall and cancer-free survival. After adjusting for patient factors (age, race, and gender), tumor characteristics (histology, grade, stage, and location) and treatment (completion of cancer-directed surgery or radiation therapy) - factors we found to be significantly associated with survival, patients who had at least 1 LN examined had a statistically significant (p<0.0001) improvement in survival as compared with those that had no LNs examined. As compared with the groups that 1 to 10 LNs examined, overall and cancer-free survival were also significantly longer (p<0.01) in the groups that had 11 or more LNs examined. There were no other significant group-wise differences. Conclusion: In order to optimize overall and cancer-free survival in esophageal cancer patients, at least 11 lymph nodes should be examined pathologically. No significant financial relationships to disclose.
GW27-e0436 Effect of Adropin on Myocardial Perfusion and Hospitalization Prognosis in Myocardial Infarction Patients after Revascularization, the ADMIRE -I study
Authors: Zhao Liangping, Shu Haizhou, Wang Li, Yao Biao, Xu Weiting, Chen Jianchang
Journal: Journal of the American College of Cardiology (2016)
TCT-430 Ancillary radial versus femoral/brachial approach to reduce vascular complications in complex coronary, peripheral and structural interventions. Preliminary results of a study from the Italian Radial Club
Authors: Bernardo Cortese, Filippo Russo, Carlo Trani, Tiziana Claudia Aranzulla, Azeem Latib, Pierfrancesco Agostoni, Alfonso Ielasi, Francesco Burzotta, Mauro De Benedictis, Alessandro Sticchi, Mario Galli, Maurizio Tespili, Antonella Tommasino, Fabio Tarantino, Antonio Colombo, Orazio Valsecchi
Journal: Journal of the American College of Cardiology (2015)
B Cell Receptor Stimulation of CLL Cells Leads to Upregulation of IRF4 Proteinexpression Influenced by SNP Expression,
Authors: Michaela Patz, Nina-Felizitas Linde, Lukas P. Frenzel, Christian P. Pallasch, Reinhild Brinker, Julia Claasen, Michael Hallek, Clemens Wendtner
Journal: Blood (2011)
Late Outcomes of Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) Diagnosed Between 1963-2002: A Report from the St. Jude Lifetime (SJLIFE) Cohort Study
Authors: Daniel A. Mulrooney, Kendra E. Jones, Kirsten K. Ness, Deborah B. Crom, Matthew J. Ehrhardt, Tara M. Brinkman, Kevin R. Krull, Wassim Chemaitilly, Larry E. Kun, Sue C. Kaste, Gregory T. Armstrong, Deokumar Srivastava, Mary V. Relling, Ching-Hon Pui, Sima Jeha, John T. Sandlund, Daniel M. Green, Leslie L. Robison, Melissa M. Hudson
Journal: Blood (2014)
TCT-256 Prognostic value of ACEF (age, creatinine, ejection fraction) score in patients undergoing percutaneous coronary intervention after acute myocardial infarction
Authors: Jang Hoon Lee, Chang Yeon Kim, Nam Kyun Kim, Se Yong Jang, Sun Hee Park, Myung Hwan Bae, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Shung Chull Chae
Journal: Journal of the American College of Cardiology (2015)
TCT-90 Sustained Beneficial Effects of Multi-Electrode Renal Denervation on Cardiac Adaptations In Resistant Hypertension: A 24-Months Follow-Up Study
Authors: Konstantinos P. Tsioufis, Vasilios Papademetriou, Kyriakos Dimitriadis, Alexandros Kasiakogias, Athanasios Kordalis, Eirini Andrikou, Anastasios Milkas, Ioannis Liatakis, Elizabeth O. Lau, Dimitrios Tousoulis
Journal: Journal of the American College of Cardiology (2015)
Web-based automated tissue microarray system WATMAS analysis of Her2/neu expression and prognostic significance in a monoinstitutional series of 436 breast cancers
Authors: A. Lucenti, A. Ferro, E. Galligioni, D. Di Vizio, C. Doglioni, F. De Michelis, A. Sboner, F. Ciocchetta, P. Dalla Palma, M. Barbareschi
Journal: Journal of Clinical Oncology (2004)

9600 Background: We investigated the prognostic significance of Her2/neu expression using FDA approved Herceptest® and the tissue microarray (TMA) technique. We used our in-house developed WATMAS, and investigated the most appropriate scoring system to be applied to the analysis of multiple replica samples from the same tumors. Methods: WATMAS includes Beecher TMA arrayer, robotized microscope, relational database and internet technology through DHTML, XML, JavaScript and VBScript. WATMAS allowed remote analysis of the TMA slides. 436 breast cancers were analysed; complete follow-up was obtained for 185 patients (120m median f-up). Four 1 mm cores per sample (i.e.: 4 replica) were included in TMA blocks; sections were immunostained with Herceptest®. For each core we evaluated using the FDA approved score, and data were stored in the database through web interface. Scores of the 4 different replica of each case were separately analysed in order to obtain the most clinically representative value. Results: The maximum score (Maxscore) of the 4 replicas pertaining to the single case was selected as the most representative. Maxscores were distributed as follows: 0= 60%, 1= 20%, 2=12% and 3= 8%. High Maxscore was associated with high grade (p=0.03) and with poor overall and relapse free survival in the whole series of cases, and in N1/2 subgroup. Prognostic value was retained after multivariate analysis. Conclusions: Our study is one of the largest published studies of Her2/neu expression in relation to prognosis using TMA and the FDA approved Herceptest®. Our results confirm the value of TMA in the evaluation of prognostic/predictive markers in breast cancer and the need of an appropriately tailored scoring system. Our WATMAS improved reliability and ease in the evaluation of TMA and allowed remote cooperation between researchers. No significant financial relationships to disclose.
TCT-732 Hybrid Transcatheter-Thoracoscopic Ventricular Restoration: A Mini Invasive Therapeutics for Left Ventricular Anteroseptal Aneurysm
Authors: Yanping Cheng, Lon S. Annest, Kevin Van Bladel, Ryan A. Brown, Andrew Wechsler, Gerard B. Conditt, Athanasios Peppas, Greg L. Kaluza, Juan Granada, Geng-Hua Yi
Journal: Journal of the American College of Cardiology (2015)
T-Cells Redirected Against the kappa Light Chain of Human Immunoglobulins Target Mature B Cell Derived Malignancies In Vitro and In Vivo.
Authors: J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, M. K. Brenner, G. Dotti
Journal: Blood (2005)
Development of a novel intervention diagnostic assay for managing bladder cancer survivors using urinary biomarkers
Authors: C. A. Fernandez, M. F. Wszolek, A. R. Duchesne, Y. Feng, S. Patel, L. Robison, J. A. Libertino, I. C. Summerhayes, A. P. Shuber
Journal: Journal of Clinical Oncology (2008)

22097 Background: With increasing therapeutic efficacies and improved methods for early detection, the cancer survivor population has been growing steadily. As this population grows, there is a clear need for the development of more effective clinical algorithms and assays that would result in more efficient management of cancer survivors. Bladder cancer survivors typically undergo cystoscopy screening at predetermined intervals over several years as standard of care. Although the majority of patients have a high likelihood of recurrence over their lifetime, only a small percentage of the population will have recurred at the time of a scheduled cystoscopy. Therefore, the development of a triage monitoring assay with extremely high Negative Predictive Value, would identify patients undergoing unnecessary cystoscopy, resulting in more efficient and appropriate application of cyctoscopy. Our group is developing a non-invasive urinary Clinical Intervention Determining Diagnostic (CIDD) test utilizing matrix metalloproteinases (e.g. MMP-2, MMP-9). Detection of matrix metalloproteinases in the urine of cancer patients has been shown to correlate with disease status in a variety of cancers, including bladder cancer. Methods: Urine samples were collected by clean catch or catherization and stored in aliquots at −80°C. Samples from 83 bladder cancer patients and 453 cancer-free individuals were analyzed via ELISA and zymography to determine the levels of MMP-2 and MMP-9. Results: Initial studies using urinary levels of MMP-2 and MMP-9 to discriminate disease-free patients from those with bladder cancer resulted in approximately 81% (67/83) sensitivity and 71% (321/453) specificity at a fixed protein level. However, applying our proprietary CIDD algorithm correctly identified 51% (231/453) of patients who were cystoscopy negative with a Negative Predictive Value of 97% (231/231+6). Conclusion: Development of a non-invasive urinary diagnostic assay utilizing MMPs and a novel analytical algorithm can result in more efficient management of bladder cancer survivors by reducing the number of unnecessary cystocopies (51%) performed during recurrence monitoring, allowing the physician to more aggressively monitor high risk patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Predictive Biosciences Predictive Biosciences
Mutational Analysis of NOTCH1 Gene in Mature T-Cell Leukemia/Lymphoma.
Authors: Daisuke Shimizu, Tomohiko Taki, Atae Utsunomiya, Hitoshi Nakagawa, Kenichi Nomura, Yosuke Matsumoto, Kazuhiro Nishida, Shigeo Horiike, Masafumi Taniwaki
Journal: Blood (2006)
Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study
Authors: Christian Dietz, Michael Lauseker, Benjamin Hanfstein, Philippe Rousselot, Thoralf Lange, Jacqueline Maier, Letizia Foroni, Gareth Gerrard, Rodica Talmaci, Jeroen JWM Janssen, Oliver Frank, Susanne Saussele, Frank Giles, Andreas Hochhaus, Martin C. Müller
Journal: Blood (2014)
Special Report: American Academy of Ophthalmology Task Force Summary Statement for Measurement of Tilt, Decentration, and Chord Length
Authors: Jack T. Holladay, Don Calogero, Gene Hilmantel, Adrian Glasser, Scott MacRae, Samuel Masket, Walter Stark, Michelle E. Tarver, Tieuvi Nguyen, Malvina Eydelman
Journal: Ophthalmology (2016)
Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Authors: Mikkael A. Sekeres, Alan F. List, David Cuthbertson, Ronald Paquette, Deborah Latham, Manual Afable, Katarina Paulic, Thomas P. Loughran, Jaroslaw P. Maciejewski
Journal: Blood (2008)
The Impact of Monitoring Epstein Barr Virus PCR in Paediatric Bone Marrow Transplant Patients: Can It Successfully Predict Outcome and Guide Intervention.
Authors: Hayley M. Greenfield, Maged I. Gharib, Andrew J.L. Turner, Mary L. Coussons, Andrew M. Will, Ruth F. Jarrett, Mario P. Macheta, Robert F. Wynn
Journal: Blood (2004)
Glutathione S-transferase M1 (GSTM1) genotype is associated with serum 8-MOP concentration and PUVA sensitivity
Authors: S. H. Ibbotson, R. S. Dawe, S. Weidlich, A.T. Dinkova-Kostova, P. M. Farr, J. Ferguson, C. R. Wolf, G. Smith
Journal: British Journal of Dermatology (2010)
NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7
Authors: Alon Vitenshtein, Yoav Charpak-Amikam, Rachel Yamin, Yoav Bauman, Batya Isaacson, Natan Stein, Orit Berhani, Liat Dassa, Moriya Gamliel, Chamutal Gur, Ariella Glasner, Carlos Gomez, Ronen Ben-Ami, Nir Osherov, Brendan P. Cormack, Ofer Mandelboim
Journal: Cell Host & Microbe (2016)
Comparative Evaluation of Five Different Assays for Ristocetin Cofactor Activity Determination,
Authors: Silmara Aparecida Lima Montalvao, Vanessa Boury Faioto, Marina P Colella, Tania de Fatima Gomes Siegl Machado, Joyce M Annichino-Bizzacchi, Erich V De Paula, Margareth C. Ozelo
Journal: Blood (2011)